Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Mise à jour : Il y a 4 ans
Référence : NCT00813072

Femme et Homme

Extrait

The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma


Critère d'inclusion

  • Stomach Neoplasms ,Esophageal Neoplasms


Liens